B+
Bull case
30%
Probability
Target price
$43.00
Analysis reference price unavailable
Analysis 2026-11-05 · RankAlpha Sentiment Codex
QURE
uniQureCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The thesis has strengthened since the May baseline: AMT-130 now has an accepted BLA, Priority Review, a dated FDA decision, and a defined confirmatory-study plan. Q3 cash and investments of $768.4 million underpin management's stated runway into 2030.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.3.
What can break
AMT-130's 48-month cUHDRS external-control comparison was non-significant, and the confirmatory trial requires substantial recruitment and follow-up. [#SEC-8K-2026-11-04]
Momentum
7
Value
41
Sentiment
87
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $43.00 · Bear $11.00Analysis 2026-11-05; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-05 • Vendor: Data Vendor v1
Scores
As of 2026-11-05 • Model: HYBRID_IC_RP
AI Memo
As of 2026-11-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-11-05
Investment thesis
As of 2026-11-05
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-05. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $59.33
Why
Momentum7 · Δ7d +4.2
Value41 · Δ7d -0.0
Sentiment87 · Δ7d +9.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +9.3.
Contradictions & invalidation
- • AMT-130's 48-month cUHDRS external-control comparison was non-significant, and the confirmatory trial requires substantial recruitment and follow-up. [#SEC-8K-2026-11-04]
- • AMT-191 dosing had previously paused after asymptomatic liver-enzyme elevations in two patients; renewed safety findings could slow development. [#SEC-8K-2026-11-04]
- • The BLA relies on a small high-dose cohort and external control; the 48-month cUHDRS comparison was not statistically significant (p=0.144).
Catalyst clock
2026-12-31
AMT-130 confirmatory-study screening
Lead driver: Sentiment · See AI snapshot
Momentum
7
18% active weight
Current posture
7d trendImproving
Δ7d
+4.2
Δ21d
+4.8
Value
41
43% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.2
Sentiment
87
39% active weight
Current posture
7d trendImproving
Δ7d
+9.3
Δ21d
-6.3
Why this grade
Composite grade C. Momentum 6.5 / Value 40.6 / Sentiment 86.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-11-05. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-11-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-11-05 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-11-05
Fundamentals (TTM)
As of 2026-11-05
Market Cap
$1.46B
Beta
0.67
Shares Out
69.37M
P/E (TTM) · Derived
-6.1
P/S (TTM)
89.50
P/FCF (TTM) · Derived
-8.04
Rev YoY
+11.0%
EPS YoY
+77.8%
Gross Margin
+15.0%
Op Margin
-1093.2%
Net Debt
-$85.95M
Current Ratio
10.01
As of 2026-11-05 • Updated nightlySource: Internal modelMethods & Data